EPICS Conference Coverage ASCO 2020 Breast Cancer Highlights
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making coming out of the ASCO 2020 conference. How will emerging research affect treatment paradigms, ongoing clinical trials, and the development of new compounds?
Faculty Chair
Adam Brufsky, MD, PhD
Medical Director, Magee-Womens Cancer Program at the UPMC Hillman Cancer Center, Pittsburgh, PA, USA
Faculty Members
Pierfranco Conte, MD
University of Padua, Padua, Italy
William Gradishar, MD
Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Nadia Harbeck, MD, PhD
Ludwig-Maximilians-University of Munich LMU – Breast Center, Germany
Joyce A. O’Shaughnessy, MD
Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, USA
Mark D. Pegram, MD
Stanford Cancer Institute,
Stanford, CA, USA
REPORT INCLUDES STRATEGIC RECOMMENDATIONS AND KEY TAKEAWAYS ON
- Evolving Therapies for Hormone Receptor-Positive Breast Cancer
- New Therapeutic Approaches for Early Stage and Metastatic HER2+ Breast Cancer
- Advances in Triple-Negative Breast Cancer
- Insights Into Immune-Based and Chemotherapy for Breast Cancer
